Early Identification of Alzheimer's Disease With PET Scan

LOS ANGELES, March 16 /PRNewswire/ -- Westside Medical Associates of Los Angeles and Westside Medical Imaging (WMI) of Beverly Hills announce the benefit of early positron emission tomography (PET) scanning to identify Alzheimer's in its early more treatable phase. According to Dr. Norman Lepor, Professor of Medicine at the Geffen School of Medicine at UCLA and Co-director of Imaging at WMI, "the research investigators at the New York University Langone Medical Center have confirmed our long held belief that we can use advanced imaging for early identification of Alzheimer's disease in patients that have not yet developed symptoms." According to Dr. Lisa Moscone of the NYU Langone Medical Center, "treating at this early stage would have the best chance of success." According to Dr. Hooman Madyoon, Co-director of Imaging at WMI, "nearly 5 million Americans suffer from the debilitating effects of Alzheimer's with the number of Americans expected to be afflicted increasing to epidemic levels as the population ages."  

According to Dr. Elliot Kolin, lead radiologist at WMI, "the NYU research team used PET with a fluorescent imaging agent called Pittsburgh Compound B that lights up clumps of a protein called beta amyloid that is a characteristic finding of Alzheimer's disease." According to Dr. Moscone not all patients with beta amyloid plaques in their brain develop Alzheimer's, the appearance of these plaques do increase the risk.

Please feel free to contact Dr. Lepor, Dr. Madyoon or Dr. Kolin at 310-623-1150 or visit us at www.westsidemedimaging.com if you have any questions regarding imaging in patients with Alzheimer's and other neurological and cardiovascular disorders.  WMI is a national leader in imaging with capabilities including PET, 3Tesla MRI, 64 slice CT, Body and Vascular Ultrasound, ECHO and SPECT.

SOURCE Westside Medical Imaging